These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 22530687)

  • 1. Continuous infusion in haemophilia: current practice in Europe.
    Batorova A; Holme P; Gringeri A; Richards M; Hermans C; Altisent C; Lopez-Fernández M; Fijnvandraat K;
    Haemophilia; 2012 Sep; 18(5):753-9. PubMed ID: 22530687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuous infusion of recombinant factor VIII formulated with sucrose in surgery: non-interventional, observational study in patients with severe haemophilia A.
    Meijer K; Rauchensteiner S; Santagostino E; Platokouki H; Schutgens RE; Brunn M; Tueckmantel C; Valeri F; Schinco PC
    Haemophilia; 2015 Jan; 21(1):e19-25. PubMed ID: 25458982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitor incidence after intensive FVIII replacement for surgery in mild and moderate haemophilia A: a prospective national study in the Netherlands.
    Eckhardt CL; Mauser-Bunschoten EP; Peters M; Leebeek FW; van der Meer FJ; Fijnvandraat K
    Br J Haematol; 2012 Jun; 157(6):747-52. PubMed ID: 22533635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: efficacy and safety of Advate in previously treated patients.
    Négrier C; Shapiro A; Berntorp E; Pabinger I; Tarantino M; Retzios A; Schroth P; Ewenstein B
    Thromb Haemost; 2008 Aug; 100(2):217-23. PubMed ID: 18690340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A cross-sectional survey of coagulation factor VIII inhibitor in children with hemophilia A].
    Wei Q; Li G; Tang L; Chen Z; Zhen Y; Wu X; Zhang N; Zhang J; Yu G; Wu R
    Zhonghua Er Ke Za Zhi; 2014 Feb; 52(2):99-102. PubMed ID: 24739719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of inhibitor development in mild haemophilia A increases with age.
    Mauser-Bunschoten EP; Den Uijl IE; Schutgens RE; Roosendaal G; Fischer K
    Haemophilia; 2012 Mar; 18(2):263-7. PubMed ID: 21851507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency of factor VIII (FVIII) inhibitor in haemophilia A.
    Borhany M; Kumari M; Shamsi T; Naz A; Farzana T
    J Coll Physicians Surg Pak; 2012 May; 22(5):289-93. PubMed ID: 22538032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitor development in patients with hemophilia A after continuous infusion of FVIII concentrates.
    von Auer Ch; Oldenburg J; von Depka M; Escuriola-Ettinghausen C; Kurnik K; Lenk H; Scharrer I
    Ann N Y Acad Sci; 2005 Jun; 1051():498-505. PubMed ID: 16126990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intermittent injections vs. continuous infusion of factor VIII in haemophilia patients undergoing major surgery.
    Batorova A; Martinowitz U
    Br J Haematol; 2000 Sep; 110(3):715-20. PubMed ID: 10997985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stability, efficacy, and safety of continuously infused sucrose-formulated recombinant factor VIII (rFVIII-FS) during surgery in patients with severe haemophilia.
    Martinowitz U; Luboshitz J; Bashari D; Ravid B; Gorina E; Regan L; Stass H; Lubetsky A
    Haemophilia; 2009 May; 15(3):676-85. PubMed ID: 19298381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous factor VIII infusion therapy in patients with haemophilia A undergoing surgical procedures with plasma-derived or recombinant factor VIII concentrates.
    Dingli D; Gastineau DA; Gilchrist GS; Nichols WL; Wilke JL
    Haemophilia; 2002 Sep; 8(5):629-34. PubMed ID: 12199670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A.
    Kempton CL; Abshire TC; Deveras RA; Hoots WK; Gill JC; Kessler CM; Key NS; Konkle BA; Kuriakose P; Macfarlane DE; Bergman G
    Haemophilia; 2012 Sep; 18(5):798-804. PubMed ID: 22512291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A. A patient-level meta-analysis.
    Marcucci M; Mancuso ME; Santagostino E; Kenet G; Elalfy M; Holzhauer S; Bidlingmaier C; Escuriola Ettingshausen C; Iorio A; Nowak-Göttl U
    Thromb Haemost; 2015 May; 113(5):958-67. PubMed ID: 25631402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and risk factors for inhibitor development in previously untreated severe haemophilia A patients born between 2005 and 2010.
    Vézina C; Carcao M; Infante-Rivard C; Lillicrap D; Stain AM; Paradis E; Teitel J; Rivard GE;
    Haemophilia; 2014 Nov; 20(6):771-6. PubMed ID: 25039669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose continuous infusion of factor VIII in patients with haemophilia A.
    Prelog T; Dolničar MB; Kitanovski L
    Blood Transfus; 2016 Sep; 14(5):474-80. PubMed ID: 26674820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous infusion of factor concentrates in children with haemophilia A in comparison with bolus injections.
    Bidlingmaier C; Deml MM; Kurnik K
    Haemophilia; 2006 May; 12(3):212-7. PubMed ID: 16643203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No inhibitor development after continuous infusion of factor concentrates in subjects with bleeding disorders undergoing surgery: a prospective study.
    Auerswald G; Bade A; Haubold K; Overberg D; Masurat S; Moorthi C
    Haemophilia; 2013 May; 19(3):438-44. PubMed ID: 23279056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitor development in non-severe haemophilia across Europe.
    Fischer K; Iorio A; Lassila R; Peyvandi F; Calizzani G; Gatt A; Lambert T; Windyga J; Gilman EA; Hollingsworth R; Makris M;
    Thromb Haemost; 2015 Oct; 114(4):670-5. PubMed ID: 26293381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Product type and the risk of inhibitor development in nonsevere haemophilia A patients: a case-control study.
    van Velzen AS; Eckhardt CL; Peters M; Oldenburg J; Cnossen M; Liesner R; Morfini M; Castaman G; McRae S; van der Bom JG; Fijnvandraat K;
    Br J Haematol; 2020 Jun; 189(6):1182-1191. PubMed ID: 32201943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age.
    Lorenzo JI; López A; Altisent C; Aznar JA
    Br J Haematol; 2001 Jun; 113(3):600-3. PubMed ID: 11380444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.